{"name":"Vitae Pharmaceuticals, Inc.","slug":"vitae-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":579674,"revenueGrowth":530.1,"grossMargin":0,"rdSpend":35551394,"netIncome":-43982668,"cash":61846343,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2015"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNdVJyX2tSUElVUW5IXzdOVWhHWU9QMmtndWd1bzlaYU9VWDFTaGRhRnpYbWpRRFl5WHp2QWZuZC1FU2dQbUFMRTdxQW5MVGQ4UWRsRFVJMzlwc0JMQ25UcjE0Um1fZWtHekhpRTlpeV8yOUI4M2J5RXl5OUVCbDlKal9qQWFXX1AwVGJjMS1YNVhzZ2NhWkgtRU9seFRqcHRHa09scUZQNkV4UFVaVVloYXBaWFpuY1ZXX1dmM2V1d0lReDQ?oc=5","date":"2026-04-07","type":"pipeline","source":"Stock Titan","summary":"Collegium (NASDAQ: COLL) posts strong 2025 growth and seeks backing on board, pay and auditor - Stock Titan","headline":"Collegium (NASDAQ: COLL) posts strong 2025 growth and seeks backing on board, pay and auditor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE5jd3J1R3VXd2FTMHBDQklEY095bDN6TUdmTURSMHNRY0tqc19xX2pmUUxEczBxQTdKS0otcm1EY0NUZ2tEaDdJYkZha1NIVFZDTnVaNVhraGtQSjRqRFFFSnRISm1BX3Bpc1k4cG5GbVBZd2ZFRUE?oc=5","date":"2026-03-20","type":"pipeline","source":"Crain's Chicago Business","summary":"CEO transition puts pharma business in the driver’s seat at Aptar - Crain's Chicago Business","headline":"CEO transition puts pharma business in the driver’s seat at Aptar - Crain's Chicago Business","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQTy1MdGVLU001NnlfdlRibjYwY3g2MWZJeWsySU1NQnlrcXd2WHQ2YWRnT25YZGxKVVF6UDhkaXVId3JfNzRwc0MtSmY3eVJIb1E1QVZmNXFZOVRYSG5zNGt0MnlhWDUxNlkwdkh0V085ZTVXS3l4UVRuUnZuZnhHcXJ6RHBXd045ZmZwNTROZnk3ekRVaHZuQy1MNXZDLVNHR201X3hVUnlHYnZBNHduNzlSd0djdnot?oc=5","date":"2025-07-08","type":"regulatory","source":"Seeking Alpha","summary":"Syndax Pharmaceuticals: Oversold Pharma Likely To Benefit From Drug Approvals - Seeking Alpha","headline":"Syndax Pharmaceuticals: Oversold Pharma Likely To Benefit From Drug Approvals","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE91Zlo0Z21BVDg5MlIxeGxzdnBJUzJrVmVPX2lEM1FxVWtNYlpIODk3YzlIaEV0QmhyNE9jSjJNeThoQ0JhNGNhVG11ZWZVVTJLSE9WV3AxLVRQamkwYU0wNkR5dXhadDVuQ0E?oc=5","date":"2021-10-23","type":"trial","source":"Wiley Online Library","summary":"Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre st","headline":"Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynami","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPWENWRXNXZTJTUE44LVBvc0Ftek9NZjU3cWthYjIzZWJxWXJGTEd5YlpWalJRMXlOWXNQRE8xZ2dqTTRSb3VBcjFUcU9vMW9EempUR05KSGRIa0lKRG5jWkdjalI5VG1ZNmtueWE0dXg3MDRDckZsTUhqcHRYeENhUjg0RVJKS0kwanY5dkp6X2hGUQ?oc=5","date":"2021-03-12","type":"pipeline","source":"SEC.gov","summary":"sndx-10k_20201231.htm - SEC.gov","headline":"sndx-10k_20201231.htm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQUEhwRFo1WmdidGlNVENwa0JCR2ZOUjVGNTZYVjFTaWM1M3FVN0VHMGJncVM3TTc3YUM4bm85V1RpYUR1WGNMZjF1TkYzdEFJcUFrTVVVak9uUUoweEY1UGs0cF9ZM1FnRTBrYXZlY2h3ak5NaE9EQWRwbUVScEVrckxtSjdpT1c2eGozQW01dDlDVWNZN2fSAVZBVV95cUxQVmpQRlBXSGFRZjhKNC1rRHA5OTc1bFpiWnRldjV6NXhwb0Y4UFRFbGs5VjZHU21PbTA4RDJsQkVDZXYtSmszR2tZMlY3Mmd4S29NcFZudw?oc=5","date":"2019-04-08","type":"pipeline","source":"Law360","summary":"Concordia Pharma Sues Over Bowel Drug Trade Secrets - Law360","headline":"Concordia Pharma Sues Over Bowel Drug Trade Secrets - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPLVIxX3c1TUttd3RGckJDcEI5S0E3NGtQS3NaTDg0Q01QUUxENzh0eEFoLXlNSm5SdEpTY0UxeUNMOGxPLS1nZlZpN21peXlFVlloVmhsWFpPbF85aEJaV1hvT05EX1k3R1d4THVFRS04VzhkMExzZWNDVEZsdE5GYWUtUVVVb0NOZVYzaTQwb3V0bDBmWTVrT19Ud1hFMHpjS3B3eE1fYlpHZw?oc=5","date":"2016-10-25","type":"pipeline","source":"PR Newswire","summary":"Allergan Successfully Completes Vitae Tender Offer - PR Newswire","headline":"Allergan Successfully Completes Vitae Tender Offer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOTC01VTA0TmVseDNyZGdtbm9lbU5fVENFZ084aDNOeVVZUFptQXFJczNBQ0UyYzQwbTI5VE03ejJyZlZ0SFpSUTdOQjdaZ1VuVGlYZUVfVWRiNWt1Z29hMW5HeEE2bGh1WnBOTUtwSWNxUUdlRWphaFVHZGdDTWJWVEtweVk2b2RWdmpteVVjRG12MEZDT3FhbQ?oc=5","date":"2016-09-21","type":"pipeline","source":"Yahoo Finance","summary":"Allergan's Tobira Acquisition Represents The Highest Premium Ever Paid In Biopharma - Yahoo Finance","headline":"Allergan's Tobira Acquisition Represents The Highest Premium Ever Paid In Biopharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOaXdjUkVEZGU5TFJRckM0cUN2UkVpQWt2eW5sSlU1YlhKRFZjdmRxTlhoZnZWR1lzMWIyYTVrM2ZJSnduR3hmYUE2RDFGQ1FncHJGSVRIWnFreFVtZWl2T2g0V0I1Z0MyQW9rbm9tSnNUeGJQVVdkWnJZdjJFb1dzNTVFaHZMSkxMN1U4b25ZeXpZRWg0ZmloX04xSWo?oc=5","date":"2016-09-20","type":"pipeline","source":"BioPharma Dive","summary":"Allergan pays steep premium for Tobira and NASH drugs - BioPharma Dive","headline":"Allergan pays steep premium for Tobira and NASH drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxQcmEyU1BjZzgtMGtBOFJWNENjWGJQYjhCM25FeFU2LXMzNjlLLTM3ekZyU0dVYVpiNDFuRUlUN1paQUVNNDVlTGZ1eXdYdTFkbF84M1pHY3BfZXFMSmo5czB0UlJqclpmNW5pNWlKekZVdmN1SU0ydXdodk1GQUtzN0x4dWZtdUxXZllid1JzdFJYOTA3ekZnVnNrLXdLSGhUcjRpSWlReGMzNUJlNS1EUkp0bjlVbl96Tjc2NFpYWU13aDBvaFZDUjJETlFfN2pSY2VMd2t6WnE3dWpMbXlSMG1rSHFrUUZoWGlyU3hQcTVnSXoxdVNV?oc=5","date":"2016-09-14","type":"deal","source":"PR Newswire","summary":"Allergan to Acquire Vitae Pharmaceuticals Adding Innovative Development Programs for Dermatologic Conditions - PR Newswire","headline":"Allergan to Acquire Vitae Pharmaceuticals Adding Innovative Development Programs for Dermatologic Conditions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOb05nTjdaWHZ5SGRocHBWYlpRMGR1dTZELW9iX2lKTWtVVEZxZ3VnWTAxZDVuUEtreXBDOEx5QWFhRThyd3BZcUNoRDVrLUxxbTZWOXNxVGdza24xekVNbG05WVpiT0l4eGhkZVpDNUx5eU04dXgyaG1fWGRoZDFic1ZtV3NYbzZqeXJ3Wm5DTGhHbURQcjE1dXh3QXdabm1wdFJacUFRNDVsemZMSUdOcmd5dw?oc=5","date":"2015-10-22","type":"pipeline","source":"MDedge","summary":"BEST PRACTICES: An Oral Treatment for Moderate to Severe Plaque Psoriasis - MDedge","headline":"BEST PRACTICES: An Oral Treatment for Moderate to Severe Plaque Psoriasis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTFB3VVhZdUJ4U1FoRG4tUHNoZldUSVdHU0NIN2JZRFZwOUJTZHRPeGVTMktYS3ZsNGk0ZEs0azQ4YkcyLVl4VXMzTlN1NU9MLWZ2Um91SXBtRmxueWZHQ3VrLXJIRjdOdw?oc=5","date":"2010-11-29","type":"pipeline","source":"The New York Times","summary":"Drug Maker Hired Writing Company for Doctors’ Book, Documents Say (Published 2010) - The New York Times","headline":"Drug Maker Hired Writing Company for Doctors’ Book, Documents Say (Published 2010)","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":579674,"revenuePeriod":"2015-12-31","revenueHistory":[{"value":579674,"period":"2015-12-31"},{"value":92000,"period":"2015-12-31"},{"value":176000,"period":"2015-09-30"},{"value":162000,"period":"2015-06-30"},{"value":150000,"period":"2015-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":35551394,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-43982668,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":61846343,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}